Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
Gilead Sciences Inc. stock underperforms Monday when compared to competitors
Shares of Gilead Sciences Inc. GILD shed 1.67% to $90.59 Monday, on what proved to be an all-around dismal trading session ...
MedPage Today23h
Trial Data Helped Guide Treatment of Stage II-III Triple-Negative Breast Cancer
Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Gilead Sciences’ Anito-Cel Shows Promising Efficacy and Safety in Phase 2 Trial, Earning Buy Rating
Mizuho Securities analyst Salim Syed has assigned their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...
Fact Check: HIV drug prevents infections, but not a new 'cure' for AIDS
A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...
Baltimore City declares Dec. 1 Carlton Smith Day in honor of HIV activist's legacy
December 1st has been declared Carlton Smith Day in Baltimore City, honoring Smith's advocacy for LGBTQ+ and HIV-affected ...
FiercePharma1d
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
Gilead Sciences’ Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...
The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
securingindustry.com22h
Gilead wins $31.8m damages in falsified meds case
Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...
bovnews1d
Uncover the Reason: Why Gilead Sciences, Inc. (GILD) Stock Is Trading 48.77% Above Its 52-Week Low?
Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.34 which represents a slight increase of $1.75 or 1.93% from the prior close of $90.59. The stock opened at $91.35 and ...